class="wp-theme-Newspaper supp-body td-standard-pack global-block-template-1 tdc-header-template tdc-footer-template td-animation-stack-type0 td-full-layout"
PCOS: use in combination with myo-inositol at physiological 40:1 myo/DCI ratio. High-dose DCI alone may impair oocyte quality (Bevilacqua studies). Pregnancy: myo-inositol studied for gestational diabetes; DCI balance important. Drug interactions: insulin (additive hypoglycaemia).
Inositol stereoisomer preferentially studied for insulin sensitisation in PCOS. Works synergistically with myo-inositol in 40:1 ratio. Independent high-dose DCI may be counterproductive.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly safe | — |
| Pregnancy | Possibly safe | — |
| Elderly | Possibly safe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)